Unknown molecular target; cellular phenotype

Unknown molecular target; cellular phenotype is a designation used in drug discovery to describe a scenario where a therapeutic agent produces a measurable biological effect in a cell-based or organismal assay, but the specific molecular target responsible for this effect has not yet been identified (Moffat et al., 2017, Nature Reviews Drug Discovery). This approach, termed phenotypic drug discovery (PDD), contrasts with target-based discovery by prioritizing the physiological response over a predefined molecular hypothesis (Swinney and Anthony, 2011, Nature Reviews Drug Discovery). Historically, many first-in-class medicines were discovered through phenotypic screens, particularly in fields like anti-infectives and CNS disorders where the underlying pathology is complex (Vincent et al., 2022, Journal of Medicinal Chemistry). However, the absence of a known target complicates the optimization of drug potency and the assessment of potential safety risks, as structure-activity relationships cannot be modeled against a protein binding site. Modern chemical biology techniques, such as affinity chromatography and genomic profiling, are frequently employed to perform target deconvolution on these phenotypic hits to satisfy regulatory requirements and enable precision medicine (Moffat et al., 2017, Nature Reviews Drug Discovery). Consequently, this label serves as a placeholder for compounds in the early stages of development or for those whose primary molecular trigger remains elusive despite clinical efficacy.

Other names

Phenotypic targetUnidentified molecular targetPhenotypic screening hitOrphan mechanism of action

Phenotypic modulation (unidentified molecular target)